Alpenglow Biosciences
Alpenglow Biosciences is a Seattle-based 3D spatial biology platform company that sells Hardware Open-Top Light-Sheet microscopy (3Di), volumetric data management (3Dm), AI-powered analysis (3Dai/Summit AI), and 3D Histology Imaging Services to biopharma, clinical pathology labs, and academic medical centers.
- Company typePrivate
- Founded2018
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alpenglow Biosciences does
Alpenglow Biosciences is a Seattle-based 3D spatial biology platform company, founded in 2018, that builds hardware and software infrastructure for non-destructive volumetric tissue imaging and AI-powered analysis. Its core technology is the patented Hybrid Open-Top Light-Sheet (HOTLS) microscopy platform, branded as the 3Di HOTLS microscope and the 3Deep Imager, which captures intact tissue volumes up to 12.5 cm × 7 cm × 1 cm without physical sectioning. The integrated Aurora 3D Spatial Biology Solution combines 3Di for imaging, 3Dm for volumetric data management, and 3Dai for AI-powered quantification; the newer Summit AI extends this into foundation-model-driven digital pathology (initially dermatology), and LUMI provides an intuitive user interface with smart-microscopy automated region-of-interest detection. The company states it is trusted by eight of the top 10 pharmaceutical companies and has named collaborations with Mayo Clinic, CorePlus, MD Anderson Cancer Center, and Penn State College of Medicine, alongside strategic partnerships with ZEISS (joint inverted light-sheet development), Molecular Instruments (HCR RNA imaging), NVIDIA Inception (GPU pipeline), Virdx (AI prostate diagnostics), and PathNet (clinical urologic oncology diagnostics).
Alpenglow operates a hybrid go-to-market: (1) a 3D Histology Imaging Services offering in which customers send tissue samples for end-to-end processing and quantitative analysis; (2) capital sales of the 3Di HOTLS instrument for in-house imaging; and (3) subscription/recurring revenue through Summit AI, 3Dm, and 3Dai. Pricing is quote-based and not publicly disclosed, with multi-year contracts common in services and instrument deployments and annual subscriptions for software. The company sells primarily to biopharmaceutical companies (drug development, biomarker discovery), clinical diagnostics/pathology labs (with an early focus on urologic oncology), translational and immunology researchers, and academic medical centers, with go-to-market executed through scientific conferences, advisory-board engagement, and strategic partnerships.
The company is venture-backed and government-funded rather than primarily equity-funded, having secured over $24M from ARPA-H (five-year, up to $21M for precision tumor removal under Cancer Moonshot) and NIH SBIR Phase II ($2M for prostate cancer diagnostics) in 2024, plus a $1.6M Washington Cancer Research Endowment Fund grant in 2023 and prior Dynamk Capital and Creative Destruction Lab participation. Advisory leadership includes a scientific co-founder who is a University of Washington professor leading the ARPA-H contract, plus digital pathology, AI cancer detection, and life-sciences tools executives.
Alpenglow Biosciences firmographics
Firmographics- Name
- Alpenglow Biosciences
- Legal name
- Alpenglow Biosciences, Inc.
- Website
- https://alpenglowbiosciences.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alpenglow Biosciences is a Seattle-based 3D spatial biology platform company that sells Hardware Open-Top Light-Sheet microscopy (3Di), volumetric data management (3Dm), AI-powered analysis (3Dai/Summit AI), and 3D Histology Imaging Services to biopharma, clinical pathology labs, and academic medical centers.
- Ownership category
- akta.pro rank
Alpenglow Biosciences industry classification
Industry- Product category
- Digital Pathology Instruments
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
- akta.pro secondary industries
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Medical Imaging AI (HDAAAEAH), 3D Vision, Depth Sensing & Point Cloud Analytics (HDAAAEAK), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Alpenglow Biosciences is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alpenglow Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Imaging Services: End-to-end 3D imaging and quantitative analysis services where customers send tissue samples for processing.
- 3Di HOTLS Instrument Sales: Sale of in-house 3Di Hybrid Open-Top Light-Sheet microscope for customers wanting to establish in-house imaging capabilities.
- Summit AI Analysis Platform: Cloud-based AI analysis platform generating quantitative tissue signatures and spatial profiles from full-sample 3D imaging data.
- Software and Data Management: 3Dm data management and 3Dai AI-powered analysis tools for processing volumetric datasets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Imaging Services |
| One time/ perpetual license | Multi-year contract | 3Di HOTLS Instrument |
| Subscription | Annual | Summit AI Platform Access |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Alpenglow Biosciences product offering
Product offeringCore offering
Alpenglow Biosciences provides an end-to-end 3D spatial biology platform, the Aurora 3D Spatial Biology Solution, which combines intact tissue imaging using proprietary Hybrid Open-Top Light-Sheet (HOTLS) microscopy, volumetric data management (3Dm), and AI-powered quantitative analysis (3Dai, Summit AI) to generate spatial profiles from whole tissue volumes. The company sells the 3Di HOTLS microscope as capital equipment, provides 3D Histology Imaging Services where customers ship samples for processing, and offers the Summit AI cloud analysis platform on subscription.
Product overview
Alpenglow Biosciences offers the Aurora 3D Spatial Biology Solution, an integrated platform for high-resolution whole-tissue 3D imaging, volumetric data management, and AI-powered quantitative analysis. The platform comprises three core modules: 3Di HOTLS (Hybrid Open-Top Light-Sheet microscope) for dual-path open-top light-sheet imaging of intact tissue up to 12.5 cm × 7 cm × 1 cm; 3Dm for aligning, organizing, and processing large multichannel volumetric datasets; and 3Dai for AI-powered quantification of cells, structures, and spatial patterns. The company also offers Summit AI as a foundation-model-based platform for 3D tissue analysis and digital pathology, and LUMI as an intuitive software interface for the 3Di HOTLS microscope. 3D Histology Imaging Services provides end-to-end imaging and analysis for clients sending samples. The platform is trusted by leading research teams and eight of the top 10 pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Brands
- Aurora 3D: 3D Spatial Biology Solution connecting intact tissue imaging, spatial profiling, and AI-powered analysis
- 3Di
- 3Dm
- 3Dai
- Summit AI
- LUMI
- 3D Derm Score
Products and services
- Aurora 3D Spatial Biology Solution
Quantifiable outcome
- >10x faster processing of multi-terabyte 3D microscopy datasets using GPU-accelerated pipelines
- +2 more outcomes
Companies that use Alpenglow Biosciences
Customer profileNamed customers5 records
Segments8 records
Ideal customer profiles3 records
Alpenglow Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Alpenglow Biosciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- PathNetcoreStrategic partnership to advance clinical-grade 3D AI diagnostics in urologic oncology. Combines PathNet's national pathology network and outcomes-linked tissue archives with Alpenglow's clinical 3D pathology platform including volumetric imaging and AI-powered spatial analytics. Initial focus on prostate and bladder cancer with goal of moving beyond 2D histology toward predictive, full-volume tissue insight in real clinical workflows.
- VirdxcoreMulti-year, milestone-based agreement to advance AI-enabled prostate cancer diagnostics. Alpenglow supplies whole-tissue 3D light-sheet microscopy datasets capturing architectural context, cellular detail, and rare features not visible with current clinical imaging modalities. Virdx uses NVIDIA GPU-enabled pipeline (>10x faster than CPU) to process multi-terabyte 3D microscopy datasets for enhancing MRI-based prostate cancer diagnostics.
- NVIDIA InceptionminorAlpenglow is a member of NVIDIA Inception, a global program for cutting-edge startups, enabling access to NVIDIA GPU technology and expertise for accelerating 3D microscopy data processing.
- ZEISScorePartnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline for clinical applications. Combines ZEISS's light-sheet imaging technologies including ZEISS Lattice Lightsheet 7 and arivis software with Alpenglow's innovative data processing and AI capabilities. Aims to create fastest whole tissue imaging solution for research, translational and clinical applications.
- CorePluscorePartnership with CLIA-certified clinical and anatomic pathology laboratory to bring 3D spatial biology to clinical research and drug development. CorePlus invested undisclosed sum and received access to Alpenglow's 3Deep Imager. Collaboration on AI-enabled smart microscopy and 3D cancer database for automating detection of regions of interest in cancer biopsies.
- Mayo CliniccoreCollaboration to integrate Alpenglow's 3D spatial biology platform including high-throughput 3D imaging, automated data processing, and AI-powered spatial analysis to accelerate drug development and advance clinical diagnostics. Platform integrated with multi-omics approaches including multiplex immunofluorescence and single cell sequencing.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
Alpenglow Biosciences competitors and assessment
Company assessmentDirect peers
- 10x Genomics: Public spatial-biology company offering the Xenium in situ platform for spatial transcriptomics/proteomics, directly competing with Alpenglow's 3D spatial biology solution for pharma and translational research customers.
- Akoya Biosciences: Public spatial-biology company offering the PhenoCycler (CODEX) platform for multiplexed spatial proteomics, directly competing with Alpenglow in immuno-oncology and translational pharma research.
- Bruker (NanoString): Bruker acquired NanoString's assets, including the CosMx spatial molecular imaging platform, making it a direct competitor in spatial-biology workflows targeting pharma and clinical research.
- Miltenyi Biotec: Offers MACSima and other spatial-biology solutions for high-content tissue analysis, directly competing with Alpenglow in pharma and academic translational research applications.
- LifeCanvas Technologies: Specialist in tissue clearing and light-sheet microscopy services and reagents, overlapping with Alpenglow's 3D HOTLS imaging services and workflow for intact-tissue analysis.
- PathAI: AI-powered digital pathology company developing diagnostic and biomarker algorithms for pharma and clinical customers; competes with Alpenglow's Summit AI platform in digital pathology.
- Paige.AI: Digital pathology AI company with FDA-cleared products, competing in AI-enabled cancer diagnostics and computational pathology with foundation-model approaches.
Broad incumbents
- ZEISS: Large microscopy incumbent offering Lattice Lightsheet 7 and arivis software; both a co-development partner and broad incumbent competitor across research and clinical light-sheet imaging.
- Leica Microsystems (Danaher): Major microscopy and histology instrument provider within Danaher, competing in advanced imaging instrumentation used by research and clinical pathology customers.
Emerging players
- Proscia: Digital pathology software company focused on AI-enabled workflows for pathology labs and biopharma, partially overlapping with Alpenglow's 3Dai and Summit AI software offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Alpenglow Biosciences social profiles
Digital presenceAlpenglow Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alpenglow Biosciences leadership team
Management profileNumber of profiles
Profiles8 records
Alpenglow Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alpenglow Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alpenglow Biosciences
What does Alpenglow Biosciences do?
Alpenglow Biosciences provides an end-to-end 3D spatial biology platform, the Aurora 3D Spatial Biology Solution, which combines intact tissue imaging using proprietary Hybrid Open-Top Light-Sheet (HOTLS) microscopy, volumetric data management (3Dm), and AI-powered quantitative analysis (3Dai, Summit AI) to generate spatial profiles from whole tissue volumes. The company sells the 3Di HOTLS microscope as capital equipment, provides 3D Histology Imaging Services where customers ship samples for processing, and offers the Summit AI cloud analysis platform on subscription.
Is Alpenglow Biosciences a public or private company?
Alpenglow Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alpenglow Biosciences founded?
Alpenglow Biosciences was founded in 2018. It employs 11 to 50 people.
Where is Alpenglow Biosciences based?
Alpenglow Biosciences is headquartered in Seattle, United States, in the North America region.
How does Alpenglow Biosciences make money?
Four revenue lines are on record. Imaging Services are the primary driver. The others are 3Di HOTLS Instrument Sales, summit AI Analysis Platform and software and Data Management.
Who are Alpenglow Biosciences's main competitors?
Direct peers on record are 10x Genomics, Akoya Biosciences, Bruker (NanoString), Miltenyi Biotec, LifeCanvas Technologies, PathAI and Paige.AI. Broad incumbents are ZEISS and Leica Microsystems (Danaher). Proscia is listed as an emerging player.
Does Alpenglow Biosciences have an API?
No public API is recorded for Alpenglow Biosciences.
What industry is Alpenglow Biosciences in?
Alpenglow Biosciences's product category is Digital Pathology Instruments. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 541714 and its SIC code is 3826.